Compare Illumina, Inc. (ILMN) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Quantum Computing Inc — how do they compare? Illumina, Inc. trades at $191.04 (market cap $27.94B), while Quantum Computing Inc trades at $8.08 (market cap $1.79B). The key difference: Illumina, Inc. is far larger — about 15.6× Quantum Computing Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | QUBT | |
|---|---|---|
Market Cap | $27.94B | $1.79B |
Sector | Health | Technology |
52-Week High | $194.33 | $24.62 |
52-Week Low | $91.00 | $6.31 |
Enterprise Value | $29.33B | $803.83M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Quantum Computing Inc. (QUBT) trades at $7.92, up 1.54% today, while technical indicators signal a bearish trend. The company shows minimal revenue of $682,000 for 2025 with a net loss of $18.67 million, resulting in negative profit margins. Analysts maintain a bullish consensus with a $26 price target, citing potential from commercial backlog and policy support, despite ongoing cash burn and a recent legal investigation into corporate governance.
QUBT offers high-risk, high-reward potential driven by quantum computing commercialization prospects, but faces significant execution risks and financial instability. The stock's outlook hinges on revenue scaling and managing cash flow, with substantial downside if growth targets are missed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
